1. Introduction {#sec1}
===============

In 1994,*BRCA2* (breast cancer gene 2) was located in chromosome 13ql2-13 by the group led by Wooster et al. \[[@B1]\]. Transmission of this gene follows an autosomal dominant pattern with incomplete penetrance \[[@B2]\]. Soon thereafter,*BRCA2* was reported as a tumour suppressor gene based on evidence of loss of heterozygosity in 7 out of 8 familial breast cancers \[[@B3]\]. Subsequently,*BRCA2* was associated with high-risk breast and ovarian cancer with a large component of heritability \[[@B4]--[@B7]\], although the risk for ovarian cancer due to*BRCA2* is much lower than the risk associated with*BRCA1* \[[@B8]\].

Only one year after this gene was discovered, the association between*BRCA2* and pancreatic cancer was assessed by Schutte et al. \[[@B9]\]. It was found that pancreatic cancer appeared in some individuals with a history of familial breast cancer associated with*BRCA2* alterations \[[@B10]\]; thus, it was estimated that 10% of cases of pancreatic cancer have an underlying inherited component \[[@B11], [@B12]\].

Worldwide pancreatic cancer incidence has increased from 185,000 in the 1980s \[[@B13]\] to 227,000 cases per year in 2014 \[[@B14]\]. In 2007, the highest incidence of pancreatic cancer was in the Baltic countries and central and eastern Europe. In northern European countries and the UK, this cancer has risen over most recent years and is rising in countries of southern, central, and eastern Europe \[[@B15]\]. It is hypothesised that this increase could be associated with increased consumption of high-sugar or carbohydrate-rich foods \[[@B16]\] or simply reflects the ageing of the population in recent decades.

Nowadays, the primary acquired risk factors for pancreatic cancer are cigarette smoking (HR = 1.74), high alcohol consumption (HR = 1.1--1.5), obesity (body mass index \> 30; HR = 1.2--1.5), and some infectious diseases that include*Helicobacter pylori (HR = 1.5)*,*Hepatitis B virus,* or*Human Immunodeficiency virus* \[[@B17]--[@B19]\]. Interestingly, other studies suggested that heavy consumption of cooking and table salt appeared to be significantly associated with pancreatic cancer (*P* = 0.009 and *P* = 0.0001, resp.), and a similar correlation was found with smoked food (*P* \< 0.01) \[[@B20]\].

Interestingly, observational studies link pancreatic cancer incidence to cadmium, arsenic, and lead exposure \[[@B21]\]. The countries with the highest levels of arsenic (more than 10 *μ*g/L, values recommended by the World Health Organization \[[@B22]\]) are those with highest incidence of pancreatic cancer. These countries include Baltic countries (especially Finland) and central and eastern European countries such as Austria, Czech Republic, Slovakia, and Hungary \[[@B23]\].

Pancreatic cancer has long been related to family history of pancreatic cancer (HR = 2.20, 95%; CI = 1.16--4.19) and melanoma (HR = 1.74, 95%; CI = 1.03--2.95), upon breast, ovarian, lung, gastrointestinal, or prostate cancer \[[@B24]\]. In addition, diabetes has also been associated with pancreatic cancer (HR = 1.4--2.2) \[[@B25]\].

Surgical resection is currently the best option so far to improve survival \[[@B26]\]. Mean life expectancy for pancreatic cancer is 1.4 years reaching 3.5 years for surgically resected patients versus 0.8 years for nonoperated patients (*P* \< 0.001) \[[@B27]\]. However, cancers of the pancreas are usually asymptomatic, and the disease only becomes apparent after the tumour invades surrounding tissues or metastasises to distant organs \[[@B28]\]. As a result, there is a pressing need to find new approaches and strategies; of these, targeted therapies hold particular promise, and*BRCA2* is one such therapy that has great potential.*BRCA2* regulates sister chromatid cohesion and/or alignment \[[@B29]\] and plays a key role in response to DNA damage by direct regulation of RAD51 recombination ([Figure 1](#fig1){ref-type="fig"}).

2. *BRCA2* in DNA Damage Response {#sec2}
=================================

The first attempt to associate*BRCA2* with DNA damage response was as a cofactor associated with human RAD51-dependent DNA repair of double-strand breaks through 8 evolutionarily conserved BRC motifs encoded in exon 11 of*BRCA2* ([Figure 1](#fig1){ref-type="fig"}) \[[@B30]\]. The milestone of DNA strand exchange is RAD51 protein which is closely related to other tumour suppressor genes such as*TP53*,*ATM*,*BRCA1*,*BLM,* and*FANCD2*. Preclinical studies showed that*BRCA2* disruptions sensitize mice embryos to ionising radiation \[[@B30]\], which was previously observed in*RAD51* knockout mice embryos \[[@B31]\]. Furthermore, mice carrying truncations on*BRCA2* loci were one-third smaller than their wild-type littermates and had improper tissue differentiation, sterility, and a shorter overall survival \[[@B32], [@B33]\].

On the other hand,*BRCA2* is essential for repair of double-strand breaks by homologous recombination \[[@B34]\].*BRCA2* alterations led to elevated P53 and P21 expression, spontaneous accumulation of chromosomal abnormalities, and aberrant chromatid exchanges, which suggests its role in pancreatic tumorigenesis ([Figure 2](#fig2){ref-type="fig"}). The aforementioned properties make*BRCA2* a crucial factor to maintain cell homeostasis.

3. *BRCA2* as a Prognostic Biomarker of Pancreatic Cancer {#sec3}
=========================================================

*BRCA2* inactivation is due mainly to genomic mutations. The most common mutations of*BRCA2* found in pancreatic cancer patients are 6174delT frameshift mutation, 6158insT mutation, splice site mutation 16-2A \> G, and the splice site mutation 15-1G \> A \[[@B35], [@B36]\]. Another variant located in the 3′-untranslated region is significantly associated with lower expression of brca2 RNA and, consequently, with sporadic pancreatic cancer (HR = 1.3; *P* \< 0.0001) \[[@B37]\].*BRCA2* inactivation has been reported to be a late event in sporadic pancreatic tumorigenesis \[[@B38]\] preceded by*KRAS* mutation (G12D) or loss of*TP53* \[[@B39], [@B40]\]. Overall,*BRCA2* could be used to determine patient prognosis.

Ashkenazi Jews have been one of the most closely studied ethnic groups concerning the significance of*BRCA2* mutations and family involved pancreatic cancer. Struewing et al. found that \>90% of Ashkenazi patients that carried*BRCA2* mutations detected in blood sample showed an association with increased risk of pancreatic cancer \[[@B41]\]. The 6174delT mutation of*BRCA2* was determined to be present in 1% (CI = 0.6--1.5) of 1.255 Jewish individuals \[[@B42]\]. Another study performed with 26 European families reported that 19% (CI = 7% to 39%) of the families with first-degree relatives with pancreatic cancer had either a mutation or a splice variant of*BRCA2* \[[@B43]\]. Murphy et al. reported 17% of*BRCA2* mutations in 31 samples from pancreatic cancer patients with at least two first-degree relatives affected by pancreatic cancer \[[@B35]\]. One study found 6% (10 of 180 families) with*BRCA2* mutation and moderate or high-risk pancreatic cancer predisposition and 6% (8 of 146) of families that presented two or more first-degree relatives affected with pancreatic cancer \[[@B44]\].

This kind of studies performed with high-risk pancreatic cancer families provides a true enlightenment of*BRCA2*-associated pancreatic cancer; however,*BRCA2* has not been directly related to patient outcome.

Pancreatic cancers with a high familial component are associated with mutations not only in*BRCA2* but also in*ATM, CDKN2, PALB2, PRSS1, STK11, or* mismatch repair (MMR) family genes \[[@B45]\]. MMR genes allow continuous point mutations in repeats regions of DNA known as microsatellites that become unstable. Alterations in microsatellites are found in oncogenes associated with initiation and progression of cancer \[[@B46]\]. Several MMR genes are involved in the acquisition of aggressive phenotype of cancer \[[@B47]\]. For example, alterations on EXO1, MLH1, MSH2, MSH3, MSH6, PMS2, PMS2L3, RECQL, TP73, and TREX1 were statistically significantly associated with overall survival of pancreatic cancer patients \[[@B48]\]. Nevertheless, the predisposition to pancreatic cancer by MMR family genes is due mainly to mutations in*MLH1* and*MSH2* and it is estimated to be \<5% \[[@B49]\].

4. *BRCA2* as Predictive Biomarker in Pancreatic Cancer {#sec4}
=======================================================

*BRCA2* mutations impair DNA repair; thus, they are considered biomarkers of genomic instability and DNA damage repair deficiency. Therefore,*BRCA2* mutations could be used as predictive biomarkers of response to some DNA damage agents. Some of these compounds include platinum-based agents and PARP inhibitors. They are considered targeted therapies indicated for BRCA2-positive tumours according to some good results achieved in clinical trials \[[@B50]\]. Platinum-based drugs are, despite their toxicity, one of the gold-standard chemotherapies administered to pancreatic cancer patients. Cisplatin, carboplatin, and oxaliplatin are some of the mostly used in clinical practice and allow cross-linking and forming DNA adducts which trigger apoptosis cascade \[[@B51]\].

Oliver et al. presented a cohort of pancreatic cancer patients; of them, those with family history of breast, ovarian, or pancreatic cancers showed significantly increased survival after platinum-based chemotherapy compared to other patients without family history (22.9 versus 6.3 months, *P* \< 0.01) \[[@B52]\]. A case report of a 60-year-old pancreatic adenocarcinoma patient carrying the*BRCA2* mutation, 1153insertionT, presented recurrence after gemcitabine treatment but showed a complete response after cisplatin and gemcitabine as second-line therapy \[[@B53]\]. Subsequently, another study with pancreatic cancer patients with positive*BRCA1/2* mutations showed improved outcome after treatment with platinum-based chemotherapy. Here, patients with locally advanced disease were pathologically downstaged and those with metastatic disease had significant increase in their progression-free survival \[[@B54]\]. Golan et al. reported that stage III/IV patients treated with platinum-based chemotherapy carrying*BRCA1/2* mutations had improved overall survival*compared to* those patients treated with other drugs (22 versus 9 months, resp.; *P* = 0.039) \[[@B55]\]. One study reported that 5 out of 8 patients with pancreatic ductal adenocarcinomas that were treated with platinum-based chemotherapy presented*BRCA2* mutation. Of these 5 patients, 2 had complete radiological response and 2 had partial responses to platinum treatment \[[@B56]\]. All the above-mentioned studies suggest that*BRCA2* mutations predict not only platinum response but also better outcome and longer survival for pancreatic cancer patients with advanced disease.

Poly(ADP-ribose) polymerase inhibitors (PARPi) prevent the repair of double-strand DNA breaks, homologous recombination, and replication repair performed by the PARP family of proteins \[[@B57]\]. A preclinical study with CAPAN-1 cell line has suggested that 6174delT mutation of*BRCA2* is highly sensitive to PARPi \[[@B58]\]. However, another study also performed with pancreatic cancer cell lines reported how a PARPi increases sensitivity to chemoradiotherapy independently of*BRCA2* mutation status \[[@B59]\].

A different drug popularly used in pancreatic cancer treatment is gemcitabine and is able to induce DNA damage response and PARP degradation \[[@B60]\]. Gemcitabine in combination with PARPi showed promising antitumor activity compared to PBS, gemcitabine, or PARPi alone, in in vivo models of pancreatic cancer \[[@B61]\].

In clinical studies,*BRCA2*-positive status has been associated with better response to PARPi alone or in combination with other drugs. In one study, 3 out of 4 patients with a known*BRCA1* or*BRCA2* mutation showed partial response after receiving PARPi alone or in combination with platinum-based chemotherapy \[[@B62]\]. In a phase I/II trial of PARPi in combination with 5FU and oxaliplatin that included 2 patients with*BRCA2* mutation, one showed a partial response and the other achieved complete response \[[@B63]\]. Another phase IB trial of PARPi in combination with gemcitabine and platinum-based chemotherapy reported that*BRCA*-mutated patients achieved partial response in 56% and stable disease in 44% of cases. However, 62% of*BRCA* wild-type patients remained with stable disease and 25% with progression \[[@B64]\].

To date, personalised therapies in pancreatic cancer could improve patient survival if assisted by breakthrough techniques used in molecular diagnosis. Deep sequencing currently offers a high-throughput method of dissecting the underlying mechanisms of tumorigenicity, leading to new strategies for personalised medicine. However, pancreatic cancer genotype is highly heterogeneous, and this heterogeneity involves its therapeutic ineffectiveness \[[@B65]\]. The IMPaCT clinical trial was set out to improve patient survival using deep sequencing to guide treatment decisions. In the study, patients carrying BRCA2 mutations were eligible to receive targeted treatment based on 5FU and mitomycin versus gemcitabine alone \[[@B66]\]. Nevertheless, no consistent conclusions arose from this trial due to the low number of patients recruited with*BRCA2* mutations \[[@B67]\].

Nevertheless, patients could present acquired resistance to platinum-based chemotherapy by accumulation of secondary genomic alterations, such as*BCR-ABL* point mutations, in which case the*BRCA2* mutation effect is bypassed \[[@B68]\].

[Table 1](#tab1){ref-type="table"} summarises ongoing or recently completed clinical trials recruiting*BRCA2* mutated pancreatic cancer patients.

5. Conclusions {#sec5}
==============

Pancreatic cancer is one of the most deadly cancers worldwide, and despite new methods of early diagnosis, surgery, and drug discovery, tumour cells tend to scatter and metastasise to vital organs, thereby reducing survival significantly. It is also highly resistant to treatments and responds poorly to chemoradiotherapy; indeed, chemoradiotherapy is used in most of cases as a palliative therapy. Therefore, patients are encouraged to participate in clinical trials regardless of disease stage.

Some studies attribute the increasing incidence of sporadic pancreatic cancer to the ageing of the population. However, several studies have reported different factors associated with this neoplasm. Obesity, cigarette smoking, high alcohol intake, and chronic pancreatitis are the most relevant factors \[[@B69]\].

On the other hand, it is estimated that 10% of pancreatic cancer cases are due to an inherited syndrome \[[@B11], [@B12]\] caused by mutations in the*BRCA1* or*BRCA2* genes \[[@B10]\]. Most of the clinical studies that relate pancreatic cancer to*BRCA2* mutations have been performed on Ashkenazim. Although this fact limits the findings\' applicability to other populations, there is nonetheless great potential in the study of the heritability of*BRCA2* mutation and pancreatic cancer incidence \[[@B41], [@B42]\].

Several preclinical and clinical studies have suggested the potential use of*BRCA2* mutations as biomarkers for DNA damage agents\' response like platinum-based chemotherapy and PARPi. Clinical trials have evaluated*BRCA2* as a predictive biomarker for use in platinum-based therapies but they were mainly retrospective and with a scarce cohort of patients. Thus, further multicenter prospective studies using larger cohorts are required to investigate multitarget therapies and their potential to minimize resistance to therapy.
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![DNA damage response model performed by BRCA2 and RAD51. Dephosphorylation of BRCA2 at Ser3291 enables RAD51 binding to BRCA2 in BRC repeats and the subsequent binding to double-strand DNA. RAD51 oligomers bind to single-strand DNA at the site of damage that enables its repairs.](BMRI2016-1869304.001){#fig1}

![Transformation model of familiar pancreatic adenocarcinoma. Ingoing arrows concern oncogenic effectors that are acquired in the cancer progression. Outgoing arrows highlight tumour suppressor factors that become inactivated in pancreatic cancer. PanIN: pancreatic intraepithelial neoplasia; CIN: chromosome instability; LOH: loss of heterozygosity.](BMRI2016-1869304.002){#fig2}
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Clinical trials for *BRCA2* mutated pancreatic cancer patients.

  Clinical trial                                                                           Phase                       Study type       Drugs                                                                 Sponsor                                     Inclusion criteria
  ---------------------------------------------------------------------------------------- --------------------------- ---------------- --------------------------------------------------------------------- ------------------------------------------- ----------------------------
    [NCT02309632](https://clinicaltrials.gov/ct2/results?term=NCT02309632&Search=Search)   Screening                   Nonrandomized    Screening of high-risk individuals                                    University of Arkansas                      Peutz-Jegher\'s Syndrome
  BRCA1 mutation carrier                                                                                                                                                                                                                                  
  BRCA2 mutation carrier                                                                                                                                                                                                                                  
  Ataxia-telangiectasia                                                                                                                                                                                                                                   
  Familial atypical malignant melanoma syndrome                                                                                                                                                                                                           
  Colorectal neoplasms, hereditary nonpolyposis                                                                                                                                                                                                           
  Hereditary pancreatitis                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                          
    [NCT02000089](https://clinicaltrials.gov/ct2/results?term=NCT02000089&Search=Search)   Prospective observational   Cohort           Human synthetic secretin                                              Johns Hopkins University                    Pancreas cancer
  Peutz-Jeghers Syndrome                                                                                                                                                                                                                                  
  Gene mutation                                                                                                                                                                                                                                           
  Germline mutation carrier                                                                                                                                                                                                                               
  Lynch Syndrome                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                          
    [NCT02775461](https://clinicaltrials.gov/ct2/results?term=NCT02775461&Search=Search)   Prospective observational   Cohort           ---                                                                   Icahn School of Medicine at Mount Sinai     Pancreas cancer
  Pancreatitis                                                                                                                                                                                                                                            
  Chronic pancreatitis                                                                                                                                                                                                                                    
  Pancreatic cyst                                                                                                                                                                                                                                         
  Family history of pancreas cancer                                                                                                                                                                                                                       
  Genetic mutations                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                          
    [NCT01585805](https://clinicaltrials.gov/ct2/results?term=NCT01585805&Search=Search)   Phase II                    Randomized       Gemcitabine, cisplatin with or without veliparib or veliparib alone   National Cancer Institute                   BRCA1 mutation carrier
  BRCA2 mutation carrier                                                                                                                                                                                                                                  
  Metastatic pancreatic adenocarcinoma                                                                                                                                                                                                                    
  Pancreatic adenocarcinoma                                                                                                                                                                                                                               
  Recurrent pancreatic carcinoma                                                                                                                                                                                                                          
  Stage III pancreatic cancer                                                                                                                                                                                                                             
  Stage IV pancreatic cancer                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                          
    [NCT01102569](https://clinicaltrials.gov/ct2/results?term=NCT01102569&Search=Search)   Prospective observational   Cohort           ---                                                                   Columbia University                         BRCA1 mutation carrier
  BRCA2 mutation carrier                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                          
    [NCT00438906](https://clinicaltrials.gov/ct2/results?term=NCT00438906&Search=Search)   Prospective observational   Cohort           Human synthetic secretin                                              Johns Hopkins University                    Pancreatic neoplasm
  Peutz-Jeghers Syndrome                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                          
    [NCT01233505](https://clinicaltrials.gov/ct2/results?term=NCT01233505&Search=Search)   Phase I                     Interventional   Veliparib, oxaliplatin, capecitabine                                  National Cancer Institute                   Advanced solid tumors
  BRCA1 mutation carrier                                                                                                                                                                                                                                  
  BRCA2 mutation carrier                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                          
    [NCT02703545](https://clinicaltrials.gov/ct2/results?term=NCT02703545&Search=Search)   Prospective observational   Cohort           ---                                                                   Johns Hopkins University                    Peutz-Jeghers Syndrome
  Familial pancreas cancer                                                                                                                                                                                                                                
  BRCA1 mutation carrier                                                                                                                                                                                                                                  
  BRCA2 mutation carrier                                                                                                                                                                                                                                  
  Hereditary pancreatitis                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                          
    [NCT00714701](https://clinicaltrials.gov/ct2/results?term=NCT00714701&Search=Search)   Prospective observational   Cohort           ---                                                                   Sidney Kimmel Comprehensive Cancer Center   Early pancreatic neoplasia
  Familial pancreatic neoplasia                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                          
    [NCT00892736](https://clinicaltrials.gov/ct2/results?term=NCT00892736&Search=Search)   Phase I                     Interventional   Veliparib                                                             National Cancer Institute                   Advanced solid tumors
  BRCA1 mutation carrier                                                                                                                                                                                                                                  
  BRCA2 mutation carrier                                                                                                                                                                                                                                  
  Estrogen receptor negative                                                                                                                                                                                                                              
  HER2/Neu negative                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                          
  [NCT01339650](https://clinicaltrials.gov/ct2/results?term=NCT01339650&Search=Search)     Phase I                     Interventional   ABT-767                                                               AbbVie                                      Advanced solid tumors
  BRCA1 mutation carrier                                                                                                                                                                                                                                  
  BRCA2 mutation carrier                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                          
    [NCT01078662](https://clinicaltrials.gov/ct2/results?term=NCT01078662&Search=Search)   Phase II                    Interventional   Olaparib                                                              AstraZeneca                                 Advanced solid tumors
  BRCA1 mutation carrier                                                                                                                                                                                                                                  
  BRCA2 mutation carrier                                                                                                                                                                                                                                  
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